Startup · $26m raised
Sydney, NSW
Every investor coverage indicates participated in a round SpeeDx raised.
| Investor | Rounds | Invested |
|---|---|---|
| Northpond Ventures | Unnamed stage | - |
| Platinum International Healthcare Fund | Unnamed stage | - |
| Tenmile | Unnamed stage | $5,000,000 |
Companies SpeeDx acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Colin Denver | CEO | Startup Daily |
| Dr Bianca Ogden | Director | Startup Daily |
Stories naming SpeeDx. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
The NSW government has engaged Cicada Innovations, via a $7.8m grant, to operate a Westmead incubator supporting early-stage medical technology ventures; the story also recalls Allergan's $350m buyout of Elastagen.
A weekly roundup reports four Australian companies together securing about $60 million: Unyoked, SpeeDx, Mutinex and Live Verdure, with funds earmarked for European and US expansion and product development.
Sydney diagnostics developer SpeeDx banked $26 million for American expansion, with $5 million from Andrew Forrest's new fund Tenmile and follow-on support from Platinum and Northpond.
Also SmartCompany